NFlection Therapeutics, Inc., a Wayne, Pa.-based biopharma therapeutics developer dedicated to targeting disease pathways to uncover new approaches to fighting rare disease, closed a $20m Series A financing round.
Backers included venBio Partners and F-Prime Capital.
Led by Christopher Powala, president & chief executive officer, NFlection Therapeutics focuses on the discovery and development of effective, targeted therapies for rare disorders known as RASopathies that are driven by the aberrant activation of the Ras/Raf/MEK/ERK pathway. The company is working to address RASopathies through the development of first-in-class soft MEK (mitogen-activated protein kinase kinase) inhibitors as topical treatments to mitigate or treat cutaneous neurofibromas in neurofibromatosis type 1, congenital birthmarks and immunosuppressant-mediated squamous cell carcinoma. Its topical MEK inhibitors are designed to degrade rapidly in circulation to avoid systemic side effects.
The company also announced the initiation of the first clinical trial of its lead product, NFX-179 Gel, a topically applied therapy. The Phase 2a study, which followed the submission of their Investigational New Drug Application with the U.S. Food and Drug Administration, will be a safety, tolerability and pharmacokinetic/pharmacodynamic study of NFX-179 Gel in adult patients with cutaneous neurofibromatosis type-1 (NF-1). This study will evaluate three concentrations of NFX-179 Gel compared with its vehicle (placebo) in a randomized, double-blind, placebo-controlled, clinical trial of 48 patients with cutaneous neurofibromatosis type-1. The study will be conducted at five investigational centers across the United States.
FinSMEs
09/06/2020